Biden’s cannabis plans, Lophos Pharma’s Peyote dreams, and a new study pokes a hole in old anti-cannabis talking point.
Let’s dive into this week’s, canna-news.
The Biden administration’s recent recommendation to reschedule marijuana under the Controlled Substances Act (CSA) made massive waves. However, not everyone is a fan of the move. While there is no debate that the move is a positive step towards Biden’s promise of decriminalizing cannabis use — advocates say he is not going far enough.
Under the CSA, cannabis is currently classified as a Schedule 1 substance. That means that — according to the government — cannabis is as dangerous as drugs like ecstasy and heroin. Further, it means that the federal government believes that cannabis has no medical uses and that it has a high potential for abuse. Cannabis’ categorization has long been a point of contention with the Department of Health and Human Services (HHS) itself saying that it should be downgraded to Schedule 3.
As with Biden’s recommendation, however, many believe that simply rescheduling cannabis does nothing to address the racial disparities that have come from cannabis criminalization. Additionally, rescheduling would mean that millions of individuals living in states without legalization would still have no way of accessing the medicine they need. The only way to tackle all these issues, advocates say, is with full federal legalization.
Advocates say that federal legalization would allow the government to introduce crucial social equity measures. This would include things like fully expunging the records of old convicts and providing employment opportunities to these individuals. Above all, advocates wish to see the black and brown communities most affected by cannabis prohibition get a cut of the massive cannabis industry.
What do you think of the Biden administration’s recent rescheduling recommendation? Do you think the president is going far enough? Let us know in the comments!
Canadian company, Lophos Pharma, is looking to bring peyote to the masses. The company recently opened up a 10,000-square-foot facility in Ontario for the cultivation, sale, and research of peyote.
Veriheal has satisfied millions of patients nationwide by giving them access to these benefits
In Canada, peyote is under a Schedule 3 classification. Thanks to an exception that says that peyote is fair game as long as mescaline isn’t extracted; however, Lopo Pharma is good to go with their plans.
In their new facility, Lophos Pharma aims to reduce the growth cycle of peyote which typically takes up to 16 years! If successful, Lophos could bring peyote back from the brink of extinction. The company is looking to have its dried peyote buttons up for sale by next summer.
Beyond peyote production and distribution, Lophos Pharma also obtained a license to produce mescaline for research purposes. They hope to conduct research on the chemical composition of mescaline. The goal is to explore the potential effects of mescaline on various mental health issues.
A new study from the International Journal of Drug Policy has found evidence suggesting that states with legal medical cannabis have experienced reduced health insurance premiums.
The research was conducted by a group of professors from Bowling Green State University, Illinois State University, and Eastern Michigan University. The study analyzed U.S. private health insurance financial data from 2010 to 2021. The data was provided by the National Association of Insurance Commissioners.
The study found that within seven years of medical cannabis legalization states experienced a reduction in insurance premiums. Here’s how those reductions in premiums broke down:
These findings challenge old beliefs that cannabis legalization leads to more accidents and increases in health insurance premiums.
For more canna-news, lifestyle tips and consumption guides, check out Veriheal’s Content Hub. To learn more about getting your medical cannabis card, visit our home page.
What do you think of these findings? Let us know in the comments!
Cannabis reform should have been years gone by… legalization should be done now. I’m 68 been inhaling for 59 years with the only issues are the laws that govern Cannabis. Biden administration is taking way to long to fully legalize Cannabis
With the arrival of 4/20 comes the promise of festivals, mass smoke sessions, and camaraderie with fellow cannabis enthusiasts. But, while cannabis may promote social gathering for some, others prefer to consume their cannabis in the way of the introvert – that is, completely alone. If you’re not exactly a social smoker and still want…
It’s become increasingly common to hear stories of those suffering from serotonin syndrome, but for some, the full scope and depth of this mysterious condition remain shrouded in mystery. Are psychedelic drugs and cannabis capable of triggering this serious medical issue? In this post, we’ll dive into what serotonin syndrome is, how you may be…
The legendary stoner holiday 4/20 is upon us, and so are the transits and astrological happenings associated with it. As spring and warm weather begin to roll in, spirits lift, and people spend more time outside under the sun—and, of course, the stars. Smoking under the night sky is a thrilling experience. Whether you’re a…
Hash is more than just a hot trend with ancient origins: it’s the future of medical cannabis consumption. Because this form of concentrate is deliberately engineered to preserve the natural terpenes and cannabinoid profile of the cannabis plant, dabbing hash is perhaps the most efficient way to seek the potential benefits of medical marijuana –…
Cannabis use is increasing all around the world. The American marijuana industry was worth about $57 billion in 2023 and is projected to reach $444 billion by 2030, a staggering growth that reflects it as the fastest-growing industry anywhere in the world. Veriheal consistently stays abreast of current trends by conducting routine surveys among our…
Get your medical marijuana card today
Sign up in under 5 minutes
